Germany’s 2026 medical cannabis ramp is real, but the market still runs on imports

Germany’s 2026 production estimate jumps, but imports still dwarf it

Germany’s official cannabis production estimate for 2026 has risen to 13,700 kilograms. The comparable estimate for 2025 was 2,360 kilograms. That is a near sixfold increase in one year, based on International Narcotics Control Board figures used in the global controlled-substance system.

On its face, that looks like a domestic breakthrough. It is not small. It signals that more German cultivation is expected to come online in 2026, and it gives the market its clearest official number yet for how much local production Berlin expects to exist.

The harder fact sits beside it. Germany’s own regulator, BfArM, shows that the country imported 141,309 kilograms of medical cannabis flower in the first nine months of 2025 alone. The quarterly progression was 37,688 kilograms in the first quarter, 47,706 kilograms in the second, and 56,915 kilograms in the third. Even before year-end, imported flower moving into the German market was already more than ten times the size of Germany’s entire 2026 production estimate.

That is why the new number matters now. It does not show Germany replacing imports. It shows Germany adding domestic capacity inside a market that remains structurally import-led.

A later trade report, citing newly published BfArM data, said full-year 2025 medical cannabis imports crossed 200 tonnes. Even without that year-end figure, the first nine months already establish the point. Germany is expanding local cultivation, but the scale of demand moving through legal supply chains remains far larger than what domestic production is currently expected to cover.

For operators across Europe, this is not a semantic distinction. It changes where attention goes in 2026. Import permits, compliant manufacturing, batch release, wholesaling, and pharmacy access still look more commercially important than any claim that German-grown product is about to displace cross-border supply.

The market still runs through import permits, EU-GMP release, and pharmacies

The German medical cannabis system is best understood as a regulated pharmacy supply chain, not simply a cultivation story. Cannabis for medical use can be produced domestically, but it can also be imported under the rules BfArM administers through the Federal Opium Agency. In practical terms, that means foreign producers can still ship product into Germany if they meet the required controls and secure the necessary permits.

That legal point matters because some markets eventually tilt toward home-grown supply by policy design. Germany has not done that. The regulator’s own FAQ makes clear that imports remain possible under the current medical cannabis law. So the commercial contest is not only about who can grow cannabis. It is about who can deliver compliant product into the German pharmacy channel at scale.

That channel has several gates. One is import authorization. Another is manufacturing compliance. EU-GMP, the European good manufacturing practice standard, is the quality system that allows cannabis to be processed and released into legal pharmaceutical distribution. A producer may grow product abroad, but the product still has to pass through the controlled quality and release steps that make it acceptable for German medical supply. After that comes wholesale distribution and pharmacy dispensing.

This is why import-heavy markets can stay import-heavy even when domestic cultivation rises. Once a country has an established inbound system, with compliant producers abroad and release infrastructure in Europe, additional local crop does not automatically replace foreign volumes. It joins a working network that already serves prescriptions, pharmacies, and specialist distributors.

BfArM’s country-of-origin chart shows how international that network already is. As of the third quarter of 2025, Canada accounted for 66,237 kilograms of medical cannabis imports into Germany, and Portugal accounted for 42,076 kilograms. Those two countries alone represented about three quarters of the inbound volume visible in the chart. That is a large, entrenched supply base with industrial scale, regulatory familiarity, and established shipping lanes.

The data sets are not perfectly identical in scope, and that caveat matters. The INCB figure is an annual estimate for cannabis production within the international drug-control framework. BfArM’s chart tracks imported medical cannabis flower by quarter. But the size gap is so wide that the overall conclusion is unaffected. Germany’s expected domestic output is rising, yet the market is still built around imported flower arriving through controlled channels.

Another way to see the imbalance is pace. Germany imported 56,915 kilograms of medical cannabis flower in the third quarter of 2025. Spread over three months, that is close to 19 tonnes per month. The 2026 domestic production estimate of 13.7 tonnes is therefore smaller than a single month of imports at that late-2025 run rate. That is not a claim that the categories are perfectly interchangeable. It is a plain indicator of scale.

This also explains why domestic capacity has symbolic and strategic importance without yet becoming the market’s center of gravity. German cultivation can improve resilience, shorten part of the supply chain, and give policymakers more comfort about local control. It cannot, at the current forecast level, carry a market of this size by itself.

For suppliers and pharmacies, the real contest is German access, not import substitution

The practical consequence for 2026 planning is straightforward. Europe’s most important medical cannabis demand center still appears to reward cross-border supply competence more than a pure domestic-cultivation thesis.

For foreign cultivators and processors, Germany remains a market-access problem before it becomes a production-location problem. Product has to enter legally, meet the relevant quality requirements, move through batch release, and reach pharmacies through licensed distribution. That favors businesses with regulatory discipline, stable production, and partners already inside European pharmaceutical logistics.

For German domestic producers, the 2026 estimate is still meaningful. A move from 2,360 kilograms to 13,700 kilograms indicates that the local industry is no longer marginal in the way it once was. But it does not mean local operators can assume broad replacement of imported flower. They are entering a market where international suppliers already fill very large volumes and where pharmacy buyers are used to sourcing from abroad.

For pharmacies and wholesalers, the message is equally clear. Security of supply still depends on international sourcing. If imports remain the dominant input, then the businesses that manage inbound compliance, inventory, release, and distribution remain central to the economics of the sector.

For investors and corporate planners, the evidence cuts against a near-term story of German self-sufficiency. The stronger thesis is narrower and more institutional. Germany is likely to remain the principal demand sink in Europe while production, processing, and release functions stay geographically distributed across several countries. In that setup, Portugal’s cultivation base, Canada’s export position, and EU processing and release assets continue to matter.

The commercial picture becomes more complicated when demand capture is separated from supply structure. Berlin is clearly uncomfortable with the speed and shape of medical-channel growth. A draft amendment published by the Bundestag in late 2025 said imports of medical cannabis flower rose 170 percent from the first half of 2024 to the second half of 2024, while prescriptions paid by statutory health insurance rose only 9 percent over the same period. That mismatch does not prove illegitimate activity by itself, but it does explain why officials believe the medical route may be serving demand that looks broader than classic reimbursed treatment.

The federal health ministry sharpened that concern in its April 1, 2026 evaluation statement. It said the line between consumer cannabis and purely medical cannabis was becoming blurred and pointed to misuse via online platforms. In plain terms, Berlin is worried that telemedicine and mail-order flows may be opening the medical channel too widely.

That matters for operators because policy pressure may hit the demand channel before it hits supply permissions. Online prescribing standards can tighten. Mail-order controls can tighten. Documentation and verification rules can tighten. None of those changes would automatically end Germany’s need for imports. They would change which clinics, pharmacies, and distributors capture the demand, and under what compliance burden.

This is an important distinction. A government can decide that parts of the medical market are expanding too fast or in the wrong way. That is a channel-governance issue. It is not the same as saying domestic production is suddenly large enough to replace foreign supply. One debate concerns who gets access and how. The other concerns where the product physically comes from. The current data suggest the second question still has the same answer: mostly from abroad.

Berlin may tighten the medical route without changing the import-led core

The more serious reading of the 2026 production figure is not that Germany has solved supply. It is that Germany has started to build a larger domestic layer inside a much larger imported market.

That distinction should keep expectations disciplined. If Berlin were aiming to replace import dependence in the near term, the official production estimate would need to be larger by an order of magnitude, not merely several times bigger than a very small base. The current increase is enough to matter operationally. It is nowhere near enough to reorder the map.

That leaves the sector facing two different realities at once. The first is industrial. Germany remains the anchor market for European medical cannabis demand, and the supply chain serving that market still runs through international cultivation, EU-compliant processing, and pharmacy distribution. The second is political. German authorities are signaling that some forms of medical-channel growth, especially where online access and consumer-style behavior overlap, will receive closer scrutiny.

Those realities can coexist. In fact, they now define the market. A tighter front end for prescriptions does not remove the need for compliant imported product. It simply alters who can capture demand once that demand is authorized. Conversely, an expansion in local cultivation does not remove the need for imported product when total market volumes are already so much larger than projected domestic output.

That is the position Europe now has to work from. Germany is not closing itself off. It is not becoming self-sufficient. It is doing something more complicated and more durable. It is becoming a bigger domestic producer while remaining the continent’s main import destination for medical cannabis.

The evidence supports a restrained conclusion. The next phase of the German market is unlikely to be won by slogans about local supply. It will be shaped by regulatory execution, pharmacy access, manufacturing compliance, and the state’s effort to draw a cleaner boundary around the medical route. Until the production numbers move far beyond the current official estimate, the core fact stays in place: Germany’s market is getting larger, and the supply system feeding it is still built on imports.